Skip to main content
. 2023 Nov 14;11(11):e007381. doi: 10.1136/jitc-2023-007381

Table 2.

Treatment-related adverse events

Adverse event Any grade (%) Grade 3/4 (%)
Blood and lymphatic
 ITP 12.5 12.5
 Leukopenia 12.5
 Lymphopenia 12.5
 Neutropenia 12.5 12.5
 Thrombocytopenia 12.5 12.5
GI/nutrition
 Decreased appetite 12.5
 Mouth hemorrhage 12.5
 Nausea 50
 Taste disorder 12.5
 Vomiting 12.5
Investigations
 ALT increase 37.5
 AST increase 37.5
General
 Chills 75
 Eye disorder 12.5
 Fatigue 62.5
 Headache 12.5
 Hot flashes 37.5
 Malaise 12.5 12.5
 Night sweats 12.5
 Pain 12.5
 Fever 12.5
Vascular
 Dizziness 12.5
 Hypotension 12.5
Respiratory
 Dyspnea 12.5 12.5
 Hypoxia 12.5 12.5
 Pneumonitis 12.5 12.5
Cutaneous
 Petechiae 12.5
 Pruritus 25
 Rash 25

ALT, alanine aminotransferase; AST, aspartate transaminase; GI, gastrointestinal; ITP, immune thrombocytopenic purpura.